{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:59:37Z","timestamp":1792605577427,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.beem.2018.09.006","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T14:19:48Z","timestamp":1538144388000},"page":"821-835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Non-surgical management of primary hyperparathyroidism"],"prefix":"10.1016","volume":"32","author":[{"given":"Filomena","family":"Cetani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Saponaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Marcocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2018.09.006_bib1","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMcp1106636","article-title":"Clinical practice. Primary hyperparathyroidism","volume":"365","author":"Marcocci","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2018.09.006_bib2","first-page":"jc20141413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop","author":"Bilezikian","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-018-0879-z","article-title":"Clinical presentation and management of patients with primary hyperparathyroidism in Italy","author":"Saponaro","year":"2018","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2018.09.006_bib4","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1210\/jc.2007-1215","article-title":"The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years","volume":"93","author":"Rubin","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib5","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1210\/jc.2007-0219","article-title":"Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial","volume":"92","author":"Ambrogini","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib6","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/jc.2006-1836","article-title":"Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial","volume":"92","author":"Bollerslev","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib7","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1210\/jc.2004-0028","article-title":"Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism","volume":"89","author":"Rao","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib8","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/jbmr.3177","article-title":"Effect of surgery versus observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH study)","volume":"32","author":"Lundstam","year":"2017","journal-title":"J\u00a0Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.beem.2018.09.006_bib9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1210\/jc.2014-3441","article-title":"Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism","volume":"100","author":"Lundstam","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib10","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop","volume":"99","author":"Bilezikian","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib11","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1210\/jc.2014-1417","article-title":"Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism","volume":"99","author":"Marcocci","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib12","doi-asserted-by":"crossref","first-page":"16033","DOI":"10.1038\/nrdp.2016.33","article-title":"Primary hyperparathyroidism","volume":"2","author":"Bilezikian","year":"2016","journal-title":"Nat Rev Dis Prime"},{"key":"10.1016\/j.beem.2018.09.006_bib13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12020-016-0931-8","article-title":"Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism","volume":"55","author":"Viccica","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2018.09.006_bib14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.surg.2005.09.018","article-title":"25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy","volume":"138","author":"Stewart","year":"2005","journal-title":"Surgery"},{"key":"10.1016\/j.beem.2018.09.006_bib15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/cen.12398","article-title":"Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature","volume":"80","author":"Shah","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2018.09.006_bib16","first-page":"279","article-title":"Effect of gender, biochemical parameters & parathyroid surgery on gastrointestinal manifestations of symptomatic primary hyperparathyroidism","volume":"139","author":"Shah","year":"2014","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.beem.2018.09.006_bib17","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1210\/jc.2013-3978","article-title":"Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial","volume":"99","author":"Rolighed","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-125-5-199609010-00002","article-title":"Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial","volume":"125","author":"Grey","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2018.09.006_bib19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Rubin","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1359\/jbmr.2001.16.1.189","article-title":"Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism","volume":"16","author":"Zanchetta","year":"2001","journal-title":"J\u00a0Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.beem.2018.09.006_bib21","first-page":"1076","article-title":"Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism","volume":"36","author":"Akbaba","year":"2013","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2018.09.006_bib22","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib23","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s12020-015-0639-1","article-title":"Bisphosphonates and glucocorticoid-induced osteoporosis: cons","volume":"49","author":"Lems","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2018.09.006_bib24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s12020-014-0506-5","article-title":"Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros","volume":"49","author":"Rossini","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2018.09.006_bib25","first-page":"1029","article-title":"Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Menshawy","year":"2018","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.beem.2018.09.006_bib26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beem.2018.09.006_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fendo.2017.00079","article-title":"Contemporary medical management of primary hyperparathyroidism: a systematic review","volume":"8","author":"Leere","year":"2017","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2018.09.006_bib28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib29","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism","volume":"16","author":"Rossini","year":"2001","journal-title":"J\u00a0Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.beem.2018.09.006_bib31","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism","volume":"26","author":"Cesareo","year":"2015","journal-title":"Osteoporos Int J Established Result Cooperat Between Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"10.1016\/j.beem.2018.09.006_bib32","first-page":"705","article-title":"Alendronate therapy in men with primary hyperparathyroidism","volume":"15","author":"Khan","year":"2009","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinologist"},{"key":"10.1016\/j.beem.2018.09.006_bib33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jgs.15250","article-title":"Protective effect of denosumab on bone in older women with primary hyperparathyroidism","volume":"66","author":"Eller-Vainicher","year":"2018","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.beem.2018.09.006_bib34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.beem.2018.09.006_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/eem.11.84","article-title":"Cinacalc et in the management of primary hyperparathyroidism","volume":"7","author":"Cetani","year":"2012","journal-title":"Expet Rev Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.mjt.0000212703.71625.26","article-title":"The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals","volume":"14","author":"Padhi","year":"2007","journal-title":"Am J Therapeut"},{"key":"10.1016\/j.beem.2018.09.006_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride","volume":"48","author":"Padhi","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.beem.2018.09.006_bib38","unstructured":"FDA. 2011 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021688s017lbl.pdf."},{"key":"10.1016\/j.beem.2018.09.006_bib39","unstructured":"EMA2008 http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000570\/human_med_000903.jsp&mid=WC0p01ac058001d124."},{"key":"10.1016\/j.beem.2018.09.006_bib40","unstructured":"FDA. 2013 http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm340551.htm."},{"key":"10.1016\/j.beem.2018.09.006_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib42","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study","volume":"94","author":"Peacock","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/EJE-14-0877","article-title":"Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery","volume":"172","author":"Khan","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2018.09.006_bib44","first-page":"24","article-title":"Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery","volume":"58","author":"Arranz Martin","year":"2011","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.beem.2018.09.006_bib45","first-page":"655","article-title":"Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling","volume":"35","author":"Cetani","year":"2012","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2018.09.006_bib46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1530\/EJE-12-0117","article-title":"MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly","volume":"167","author":"Filopanti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2018.09.006_bib47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/2042018813482344","article-title":"Experience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment","volume":"4","author":"Luque-Fernandez","year":"2013","journal-title":"Ther Adv Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2018.09.006_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MAJ.0b013e3181379f3e","article-title":"Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy","volume":"335","author":"Iglesias","year":"2008","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.beem.2018.09.006_bib50","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.metabol.2007.11.014","article-title":"Cinacalcet for the treatment of primary hyperparathyroidism","volume":"57","author":"Sajid-Crockett","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2018.09.006_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/cen.12108","article-title":"Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group","volume":"79","author":"Saponaro","year":"2013","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2018.09.006_bib52","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.12.2010.3663","article-title":"Cinacalcet to prevent parathyrotoxic crises in hypercalcaemic patients awaiting parathyroidectomy","volume":"2011","author":"Rostoker","year":"2011","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.beem.2018.09.006_bib54","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1359\/jbmr.081018","article-title":"Parathyroid carcinoma","volume":"23","author":"Marcocci","year":"2008","journal-title":"J\u00a0Bone Miner Ress Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.beem.2018.09.006_bib55","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1210\/jcem.83.4.4726","article-title":"Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent","volume":"83","author":"Collins","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib56","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","article-title":"Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma","volume":"92","author":"Silverberg","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib57","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJM200012213432508","article-title":"Hyperparathyroid and hypoparathyroid disorders","volume":"343","author":"Marx","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.beem.2018.09.006_bib58","first-page":"18","article-title":"Hyperparathyroid genes: sequences reveal answers and questions","volume":"17","author":"Marx","year":"2011","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinologist"},{"key":"10.1016\/j.beem.2018.09.006_bib59","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/ncpendmet0816","article-title":"A\u00a0patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet","volume":"4","author":"Falchetti","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib60","doi-asserted-by":"crossref","first-page":"906163","DOI":"10.1155\/2010\/906163","article-title":"Clinical use of cinacalcet in MEN1 hyperparathyroidism","volume":"2010","author":"Moyes","year":"2010","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.beem.2018.09.006_bib61","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12020-015-0696-5","article-title":"Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1)","volume":"52","author":"Giusti","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2018.09.006_bib62","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/SLA.0b013e31824c5252","article-title":"Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database","volume":"255","author":"Keutgen","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.beem.2018.09.006_bib63","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1373\/clinchem.2006.070219","article-title":"Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl","volume":"52","author":"Henrich","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.beem.2018.09.006_bib64","first-page":"142","article-title":"Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis","volume":"117","author":"Akinci","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.beem.2018.09.006_bib65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2169\/internalmedicine.49.2705","article-title":"Medical management of primary hyperparathyroidism with concomitant multiple myeloma","volume":"49","author":"Fanari","year":"2010","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2018.09.006_bib66","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1053\/j.ajkd.2006.07.019","article-title":"Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride","volume":"48","author":"Sloand","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.beem.2018.09.006_bib67","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.surg.2006.07.032","article-title":"Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism","volume":"140","author":"Zanocco","year":"2006","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.beem.2018.09.006_bib68","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12020-013-9980-4","article-title":"Primary hyperparathyroidism in pregnancy","volume":"44","author":"Diaz-Soto","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2018.09.006_bib69","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00006254-200206000-00022","article-title":"Primary hyperparathyroidism in pregnancy: evidence-based management","volume":"57","author":"Schnatz","year":"2002","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.beem.2018.09.006_bib70","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1515\/JPEM.2009.22.8.741","article-title":"Cinacalcet for hyperparathyroidism in pregnancy and puerperium","volume":"22","author":"Horjus","year":"2009","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.09.006_bib71","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s13256-016-1093-2","article-title":"Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature","volume":"10","author":"Vera","year":"2016","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.beem.2018.09.006_bib72","first-page":"e14","article-title":"A\u00a0pregnant dilemma: primary hyperparathyroidism due to parathyromatosis in pregnancy","volume":"20","author":"Edling","year":"2014","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinologist"},{"key":"10.1016\/j.beem.2018.09.006_bib73","first-page":"140056","article-title":"The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma","volume":"2014","author":"Nadarasa","year":"2014","journal-title":"Endocrinol Diabetes Metabol Case Rep"},{"key":"10.1016\/j.beem.2018.09.006_bib74","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJM199204303261806","article-title":"Management of acute hypercalcemia","volume":"326","author":"Bilezikian","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2018.09.006_bib75","series-title":"The parathyroids","first-page":"401","article-title":"Acute primary hyperparathyroidism","author":"Fitzpatrick","year":"2015"},{"key":"10.1016\/j.beem.2018.09.006_bib76","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ando.2015.03.003","article-title":"Parathyroid carcinoma: challenges in diagnosis and treatment","volume":"76","author":"Betea","year":"2015","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.beem.2018.09.006_bib77","series-title":"The parathyroids","first-page":"409","article-title":"Parathyroid carcinoma","author":"Cetani","year":"2015"},{"key":"10.1016\/j.beem.2018.09.006_bib78","first-page":"53","article-title":"Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia","volume":"110","author":"Fountas","year":"2017","journal-title":"QJM Mon J Assoc Phys"},{"key":"10.1016\/j.beem.2018.09.006_bib79","first-page":"49","article-title":"Use of denosumab in parathyroid carcinoma with refractory hypercalcemia","volume":"108","author":"Tong","year":"2015","journal-title":"QJM Mon J Assoc Phys"},{"key":"10.1016\/j.beem.2018.09.006_bib80","article-title":"Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases","volume":"2017","author":"Rozhinskaya","year":"2017","journal-title":"Endocrinol Diabetes Metabol Case Rep"},{"key":"10.1016\/j.beem.2018.09.006_bib81","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1210\/jc.2004-1772","article-title":"Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency","volume":"90","author":"Grey","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.09.006_bib82","first-page":"420","article-title":"Safety of vitamin D replacement in patients with primary hyperparathyroidism and concomitant vitamin D deficiency","volume":"19","author":"Wagner","year":"2013","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinologist"},{"key":"10.1016\/j.beem.2018.09.006_bib83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/EC-12-0008","article-title":"Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism","volume":"1","author":"Rao","year":"2012","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2018.09.006_bib84","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/EJE-08-0901","article-title":"Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D","volume":"161","author":"Tucci","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2018.09.006_bib85","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/j.lpm.2010.08.005","article-title":"Half of the patients with primary hyperparathyroidisms have a vitamin D deficiency: aggravating the osseous attack","volume":"40","author":"Velayoudom-Cephise","year":"2011","journal-title":"Presse Med"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X18301064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X18301064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:54:37Z","timestamp":1761497677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X18301064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1521690X18301064"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2018.09.006","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-surgical management of primary hyperparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2018.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}